Fuji Pharmaceutical Industry Co., Ltd. Gene Techno Science Co., Ltd.

Fuji Pharmaceutical and Gene Techno Science announce co-development of recombinant human Granulocyte Colony Simulating Factor (rhG-CSF)

Tokyo, Japan – February 2, 2010 – Fuji Pharmaceutical Industry Co., Ltd. (Head office: Tokyo, Japan; President: Fumihiro Imai) and Gene Techno Science Co., Ltd. (Head office: Sapporo, Japan; President: Masanari Kawaminami) announced today that they have co-developed a recombinant human Granulocyte Colony Simulating Factor (rhG-CSF), the active ingredient for treating neutropenia.

Recombinant human G-CSF, synthesized using biological cells, is widely accepted and distributed for a chemotherapy drug of neutropenia. This co-development aims at the first biosimilar, or follow-on biologic, of the rhG-CSF products in Japan. They also plan a co-promotion of the product for rapid and effective market penetration.

This announcement is related to the press release on February 1, 2010 by Fuji Pharmaceutical and Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan, President: Naoyuki Mochida) about the collaboration agreement of clinical development of the rhG-CSF.

## **CONTACTS:**

FUJI PHARMACEUTICAL CO., LTD. 3-19 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, JAPAN

TEL: +81-3-3556-3344 FAX: +81-3556-4455

http://www.fujipharma.jp

GENE TECHNO SCIENCE CO..LTD.

1, Kita-2, Nishi-9, Chuo-ku, Sapporo,

060-0002, JAPAN

TEL: +81-11-876-9571 FAX: +81-11-854-8368

http://www.g-gts.com